The FDA has approved the first mRNA flu vaccine, developed by Moderna, for adults aged 50 and older, marking a significant advancement in flu prevention technology.
The U.S. Food and Drug Administration (FDA) has granted approval for the nation’s first flu vaccine utilizing mRNA technology, as announced by Moderna on Thursday. This groundbreaking vaccine is fully approved for adults aged 50 to 64 and has received accelerated approval for those aged 65 and older, allowing its use while Moderna conducts further studies to confirm its effectiveness in seniors.
The approval comes ahead of the 2026-2027 flu season and is based on a phase 3 clinical trial that included approximately 40,000 participants. Results from the trial indicated that the new mRNA vaccine led to a 27% reduction in flu cases compared to traditional flu vaccines.
Experts have highlighted the advantages of mRNA vaccines, noting their ability to be updated more swiftly in response to changes in circulating flu strains. While the new vaccine exhibited more short-term side effects than conventional flu shots—such as arm pain, fatigue, headache, and fever—these effects were generally mild and temporary. No major safety concerns were reported during the trial.
“This is not a universal vaccine, but it is geared for rapid turnaround once the yearly strains have been identified,” said Dr. Marc Siegel, a senior medical analyst at Fox News. “It’s similar to the COVID vaccine and was found to be 25% to 30% more effective than the current flu vaccine,” he added, emphasizing its focus on protecting the elderly.
Older adults are particularly vulnerable to severe influenza. According to the Centers for Disease Control and Prevention (CDC), during the 2024-2025 flu season, individuals aged 65 and older accounted for 57% of flu-related hospitalizations and 71% of flu-related deaths. An estimated 51 million Americans contracted the flu that season, leading to around 710,000 hospitalizations and 45,000 deaths.
Earlier this year, the mRNA vaccine faced a regulatory hurdle when the FDA initially declined to review Moderna’s application, citing concerns regarding the design of its clinical trial. However, Moderna contested this decision, and the FDA later agreed to proceed with the review.
In June, an independent advisory committee for the FDA concluded that the benefits of the vaccine outweighed its risks, clearing the path for its approval. Looking ahead, this approval may pave the way for combination vaccines that can protect against multiple respiratory viruses simultaneously. Moderna has expressed interest in developing a combined flu and COVID-19 vaccine, aiming to provide individuals with a single seasonal shot.
This innovative approach to flu vaccination represents a significant step forward in public health, particularly for older adults who are at greater risk for severe illness from influenza.
For more information, refer to Fox News.